title: Fibrillin-1 (FBN-1) a new marker of germ cell neoplasia in situ.
abstract: Germ cell neoplasia in situ (GCNIS), is preinvasive stage of testicular germ cell tumours (TGCTs). Fibrillins, which are integral components of microfibrils are suggested to be involved in cancer pathogenesis and maintenance of embryonic stem cells pluripotency. The aim of this study was to examine fibrillin-1 (FBN-1) expression in TGCTs patients.
  
  
  
  Surgical specimens from 203 patients with TGCTs were included into the translational study. FBN-1 expression was evaluated in the tumour tissue, in GCNIS and in adjacent non-neoplastic testicular tissue in all available cases. Tissue samples were processed by the tissue microarray method. FBN-1 was detected by immunohistochemistry using goat polyclonal antibody and the expression was evaluated by the multiplicative quickscore (QS).
  
  
  
  The highest FBN-1 positivity was detected in GCNIS (mean QS = 11.30), with overexpression of FBN-1 (QS >9) in the majority (77.1 %) of cases. Expression of FBN-1 in all subtypes of TGCTs was significantly lower in comparison to expression in GCNIS (all p <0.001). Seminoma had significantly higher expression compared to EC, ChC and TER (all p <0.05), but not to YST (p = 0.84). In non-neoplastic testicular tissue the FBN-1 positivity was very low (mean QS = 0.02). Sensitivity, specificity, positive and negative predictive value of FBN-1 expression for diagnosis of GCNIS were 97.1, 98.8, 98.6 and 97.7 %.
  
  
  
  FBN-1 is overexpressed in TGCTs and especially in GCNIS when compared to non-neoplastic testicular tissue in patients with germ cell tumors and could be involved in germ cell neoplasia in situ development.
authors.affiliation: Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
authors.forename: Z
authors.initials: Z
authors.lastname: Cierna
authors.affiliation: 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. misomego@gmail.com.|Translational Research Unit, Faculty of Medicine, Comenius University, Bratislava, Slovakia. misomego@gmail.com.|National Cancer Institute, Bratislava, Slovakia. misomego@gmail.com.|2nd Department of Oncology, Faculty of Medicine, National Cancer Institute, Comenius University, Klenova 1, 833 10, Bratislava, Slovak Republic. misomego@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Mego
authors.affiliation: Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Canada.
authors.forename: I
authors.initials: I
authors.lastname: Jurisica
authors.affiliation: St. Elisabeth Cancer Institute, Bratislava, Slovakia.
authors.forename: K
authors.initials: K
authors.lastname: Machalekova
authors.affiliation: 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.|National Cancer Institute, Bratislava, Slovakia.
authors.forename: M
authors.initials: M
authors.lastname: Chovanec
authors.affiliation: St. Elisabeth Cancer Institute, Bratislava, Slovakia.|1st Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
authors.forename: V
authors.initials: V
authors.lastname: Miskovska
authors.affiliation: Translational Research Unit, Faculty of Medicine, Comenius University, Bratislava, Slovakia.|National Cancer Institute, Bratislava, Slovakia.
authors.forename: D
authors.initials: D
authors.lastname: Svetlovska
authors.affiliation: Translational Research Unit, Faculty of Medicine, Comenius University, Bratislava, Slovakia.|National Cancer Institute, Bratislava, Slovakia.
authors.forename: K
authors.initials: K
authors.lastname: Kalavska
authors.affiliation: 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.|National Cancer Institute, Bratislava, Slovakia.
authors.forename: K
authors.initials: K
authors.lastname: Rejlekova
authors.affiliation: St. Elisabeth Cancer Institute, Bratislava, Slovakia.
authors.forename: K
authors.initials: K
authors.lastname: Kajo
authors.affiliation: 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.|National Cancer Institute, Bratislava, Slovakia.
authors.forename: J
authors.initials: J
authors.lastname: Mardiak
authors.affiliation: Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
authors.forename: P
authors.initials: P
authors.lastname: Babal
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002278:Carcinoma in Situ / Q000175:diagnosis*; D000071838:Fibrillin-1 / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000175:diagnosis*; D012680:Sensitivity and Specificity; D013736:Testicular Neoplasms / Q000175:diagnosis*; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D000071838:Fibrillin-1
keywords: Fibrillin-1; Germ cell neoplasia in situ; Testicular cancer